{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:17:32Z","timestamp":1769048252556,"version":"3.49.0"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,7,11]],"date-time":"2002-07-11T00:00:00Z","timestamp":1026345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>This Phase II trial was conducted to determine the response rate, particularly of the primary sites, tolerability, and toxicity of induction chemotherapy of paclitaxel, ifosfamide, and carboplatin for patients with previously untreated locally advanced squamous cell carcinoma of the head and neck (SCCHN). We also hypothesized that improved complete response (CR) rates with the induction chemotherapy may render better survival rates with subsequently delivered definitive local treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>All eligible patients with locally advanced SCCHN received two courses of induction chemotherapy and underwent repeated head and neck examination and computed tomography or magnetic resonance imaging scans. If the patients achieved responses (CR or partial [PR]), they received two more courses of chemotherapy before undergoing definitive local treatment. Induction chemotherapy consisted of paclitaxel (T; 175 mg\/m<jats:sup>2<\/jats:sup> in a 3\u2010hour infusion) on Day 1, ifosfamide (I; 1000 mg\/m<jats:sup>2<\/jats:sup> in a 2\u2010hour infusion) on Days 1\u20133 with intravenous mesna (200 mg\/m<jats:sup>2<\/jats:sup> before and 400 mg\/m<jats:sup>2<\/jats:sup> after ifosfamide), and carboplatin (C) using the Calvert formula for the area under the plasma concentration\u2010versus\u2010time curve of 6 on Day 1, repeated every 3\u20134 weeks. Prophylactic hematopoietic growth factors or antibiotics were not used in this study. Definitive local treatment was given based on the investigators' preference.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Fifty\u2010four patients were registered and 52 patients were assessable for response to induction chemotherapy; 2 were not evaluable. After four courses of induction chemotherapy, the CR rates of the primary and lymph node sites were 60%, and 41%, respectively. For both primary and lymph node sites, there were 31% CRs and 50% PRs with an overall response rate of 81%. Five (9%) patients developed neutropenic fever, all of whom recovered with antibiotic therapy. Two (4%) patients had infection without neutropenia and recovered without any complication. Grade 3\/4 thrombocytopenia and anemia occurred in three (6%) and four (7%) patients, respectively. Grade 3\/4 fatigue developed in four (7%), arthralgia\/myalgia in two (4%), peripheral neuropathy in two (4%), and orthostatic hypotension in two (4%) patients. One patient died of severe anaphylaxis although a maximized resuscitation effort was made. With a median follow\u2010up of 22 months, the organ preservation rate was about 81% (42 of 52 patients). Although survival rates were not primary end points in this study, with a median follow\u2010up of 22 months, 43 (83%) patients are still alive. Overall 1 and 2\u2010year survival rates were 88% and 82%, respectively. Disease\u2010free 1 and 2\u2010year survival rates were 88% and 77% respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>TIC induction chemotherapy is associated with a high CR rate at the primary sites and with excellent survival and organ preservations rates with subsequently delivered definitive local therapy. The regimen was also well tolerated in the majority of patients. The TIC regimen should be developed further in the context of induction chemotherapy followed by concomitant chemoradiotherapy or with specific molecular targeted agents. Cancer 2002;95:322\u201330. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10661<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10661","type":"journal-article","created":{"date-parts":[[2002,10,10]],"date-time":"2002-10-10T15:45:16Z","timestamp":1034264716000},"page":"322-330","source":"Crossref","is-referenced-by-count":41,"title":["Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck"],"prefix":"10.1002","volume":"95","author":[{"given":"Dong M.","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie S.","family":"Glisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadlo R.","family":"Khuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Edward","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Papadimitrakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marites","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Garden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merrill S.","family":"Kies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Clayman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waun Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,7,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280306"},{"key":"e_1_2_6_3_2","first-page":"741","volume-title":"Cancer principles and practice of oncology","author":"Schantz SP","year":"1997"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30242-5"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1983.00800160017004"},{"key":"e_1_2_6_6_2","first-page":"1645","volume-title":"Cancer medicine","author":"Clayman GL","year":"1996"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.250"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.855"},{"key":"e_1_2_6_9_2","first-page":"471","article-title":"Clinical trial of cisplatin and 5\u2010FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck","volume":"66","author":"Kish J","year":"1982","journal-title":"Cancer Treat Rep."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198810000-00009"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.265"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"issue":"6","key":"e_1_2_6_14_2","first-page":"41","article-title":"A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies","volume":"22","author":"Smith RE","year":"1995","journal-title":"Semin Oncol."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199608000-00012"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1325"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010401)91:7<1316::AID-CNCR1134>3.0.CO;2-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909009017560"},{"issue":"3","key":"e_1_2_6_22_2","first-page":"1","article-title":"Clinical toxicities encountered with paclitaxel","volume":"20","author":"Rowinsky EK","year":"1993","journal-title":"Semin Oncol."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900415)65:8<1685::AID-CNCR2820650804>3.0.CO;2-S"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-8375(97)00090-0"},{"key":"e_1_2_6_25_2","first-page":"527","article-title":"Cell kinetics of head and neck cancer","volume":"1","author":"Kotelnikov V","year":"1995","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(90)90036-J"},{"key":"e_1_2_6_27_2","first-page":"2430","article-title":"The effect of delay in treatment on local control by radiotherapy","volume":"34","author":"McKillop W","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"e_1_2_6_28_2","first-page":"13","article-title":"The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck","volume":"27","author":"Posner M","year":"2000","journal-title":"Semin Oncol."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1096"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806183382503"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2081"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.9.583"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199710)19:7<567::AID-HED2>3.0.CO;2-5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90238-0"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00088-G"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.876"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)00079-0"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous cell cancer: three meta\u2010analyses of updated individual data","volume":"355","author":"Pignon J","year":"2000","journal-title":"Lancet"},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.1994.12.2.385","article-title":"Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer","volume":"12","author":"Murthy AK","year":"1994","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.730"},{"key":"e_1_2_6_41_2","first-page":"1204","article-title":"Epidermal growth factor receptor targeted therapy with C225 and cisplatin in patients with head and neck cancer","volume":"7","author":"Shin DM","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199711000-00012"},{"key":"e_1_2_6_43_2","first-page":"2099","article-title":"PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number\u2010dependent manner","volume":"3","author":"Bos M","year":"1997","journal-title":"Clin Cancer Res."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10661","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:44:24Z","timestamp":1760265864000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,11]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,7,15]]}},"alternative-id":["10.1002\/cncr.10661"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10661","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,11]]}}}